Sjogren's Syndrome: Recent Updates

Charalampos Skarlis¹, Sylvia Raftopoulou¹, Clio P Mavragani^{1

2

3}

Affiliations

¹ Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
² Fourth Department of Internal Medicine, School of Medicine, University Hospital Attikon, National and Kapodistrian University of Athens, Haidari, 12462 Athens, Greece.
³ Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Editorial

Charalampos Skarlis et al. J Clin Med. 2022.

. 2022 Jan 13;11(2):399.

doi: 10.3390/jcm11020399.

Charalampos Skarlis¹, Sylvia Raftopoulou¹, Clio P Mavragani^{1

2

3}

¹ Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
² Fourth Department of Internal Medicine, School of Medicine, University Hospital Attikon, National and Kapodistrian University of Athens, Haidari, 12462 Athens, Greece.
³ Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Abstract

Primary Sjögren's syndrome (SS) is a chronic systemic autoimmune disorder affecting primarily perimenopausal women [...].

The authors declare no conflict of interest.

1. Mavragani C.P., Moutsopoulos H.M. Sjögren Syndrome Review. Can. Med. Assoc. J. 2014;186:579–586. doi: 10.1503/cmaj.122037. - DOI - PMC - PubMed
1. Kassan S.S., Moutsopoulos H.M. Clinical Manifestations and Early Diagnosis of Sjögren Syndrome. Arch. Intern. Med. 2004;164:1275–1284. doi: 10.1001/archinte.164.12.1275. - DOI - PubMed
1. Mavragani C.P., Crow M.K. Activation of the Type I Interferon Pathway in Primary Sjogren’s Syndrome. J. Autoimmun. 2010;35:225–231. doi: 10.1016/j.jaut.2010.06.012. - DOI - PubMed
1. Nezos A., Gravani F., Tassidou A., Kapsogeorgou E.K., Voulgarelis M., Koutsilieris M., Crow M.K., Mavragani C.P. Type I and II Interferon Signatures in Sjogren’s Syndrome Pathogenesis: Contributions in Distinct Clinical Phenotypes and Sjogren’s Related Lymphomagenesis. J. Autoimmun. 2015;63:47–58. doi: 10.1016/j.jaut.2015.07.002. - DOI - PMC - PubMed
1. Bodewes I.L.A., Versnel M.A. Interferon Activation in Primary Sjögren’s Syndrome: Recent Insights and Future Perspective as Novel Treatment Target. Expert Rev. Clin. Immunol. 2018;14:817–829. doi: 10.1080/1744666X.2018.1519396. - DOI - PubMed